Home  
  Our Team  
  Patient Info  
  Services  
   
  Pay My Bill  
  Contact Us  

News for Healthier Living

Researchers Identify Drivers of Resistance to KRAS Inhibitors in Colorectal Cancer

A new preclinical study led by researchers at The University of Texas MD Anderson Cancer Center and Weill Cornell Medicine has uncovered genetic and cell-state adaptive mechanisms that drive resistance to KRAS inhibitors in patients with KRAS-mutant colorectal cancer. These findings suggest that targeting early inflammatory responses by adding TBK1 blockade with KRAS inhibition may be a promising combination strategy to overcome treatment resistance.

May 21, 2026


June 3 2026

June 2 2026

June 1 2026

May 31 2026

May 30 2026

May 29 2026

May 28 2026

May 27 2026

May 26 2026

May 25 2026

May 22 2026

May 21 2026